Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 105 for “"Pancreatic Ductal Adenocarcinoma (PDAC)"”.
-
Heparan Sulfate Proteoglycans in Pancreatic Ductal Adenocarcinoma (PDAC)
… (HSPG), Syndecan-1 (SDC1), as a key effector for pancreatic ductal adenocarcinoma (PDAC) progression whose surface expression is driven by KRAS*. By leveraging various PDAC models, we found that surface SDC1 expression was initially diminished upon mutant KRAS (KRAS*) signaling blockade but …
-
Role of Methyltransferase Like-3 (Mettl3) In Pancreatic Ductal Adenocarcinoma (Pdac) Progression
<p>Pancreatic Ductal Adenocarcinoma (PDAC) is an aggressive cancer with about a 10% five-year survival rate. The grim prognostic situation of pancreatic cancer patients underlines the need to identify novel molecular targets. Recent studies have brought to attention, the need to therapeutically …
-
Development of novel reactive oxygen species (ROS)-modulating agents and carbonic anhydrase inhibitors for the treatment of Pancreatic Ductal Adenocarcinoma and other resistant cancers
… that showed promising antitumor activity against pancreatic ductal adenocarcinoma (PDAC) as well as other tumor types. In the same context of developing new active compounds against resistant cancer forms, I propose the study of a novel class of selective carbonic anhydrase inhibitors (CAI) …
-
Regulation of CYP3A5 in Pancreatic Ductal Adenocarcinoma
… in high amounts in some cancers, including pancreatic ductal adenocarcinoma (PDAC). There have been several published studies regarding CYP3A5 regulators, but there is still much to be discovered concerning CYP3A5 regulation in cancer. To further understand the regulation of CYP3A5, a …
-
Development and characterization of immunogenic genetically engineered mouse models of pancreatic cancer
… of immunotherapy in many cancers. However, pancreatic cancer has remained largely refractory to checkpoint immunotherapy. To uncover mechanisms of immune escape, we have characterized two preclinical models of immunogenic pancreatic ductal adenocarcinoma (PDAC). In order to dissect the …
-
PROGRAMMED ADDICTION OF PANCREATIC CANCER TO NUCLEOTIDE METABOLISM BY THE TUMOR MICROENVIRONMENT
Pancreatic ductal adenocarcinoma (PDAC) is one of the fastest growing malignancy, yet PDAC cells face a harsh tumor microenvironment (TME) of poor nutrient availability. To adapt, they were shown to exploit stellate cells, the predominant stromal cells, for growth-promoting nutrients. However, …
-
Clonal Phenotype Mapping Reveals Genomic Alterations Underlying Tumor Immunosuppression during Immunotherapy
… to either elicit or evade immune responses. In pancreatic ductal adenocarcinoma (PDAC), where immunotherapy has yet to become an effective treatment option, we investigated the role of intratumoral heterogeneity in influencing immune interactions. Using orthotopic clonal replica tumors, we …
-
Absence of Enhancer of Zeste Homolog 2 Promotes the Progression of KRAS-Driven Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is estimated to be the second deadliest cancer by 2030. Previous studies showed constitutive activation of KRAS (KRASG12D) is a key genetic driver of PDAC, accelerated by deletion of the epigenetic regulator Enhancer of Zeste Homologue 2 (EZH2). However, …
-
Targeting Stromal-Mediated Resistance Mechanisms in Oncogenic KRAS-Driven Pancreatic Ductal Adenocarcinoma
<p>Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with oncogenic KRAS mutations driving both tumor initiation and maintenance. Despite recent breakthroughs in KRAS-targeted therapies, the rapid emergence of resistance mechanisms limits their clinical efficacy. …
-
Single cell and spatial analysis characterize metabolic DPEP1+ fibroblasts in PDAC
<p>Pancreatic ductal adenocarcinoma (PDAC) is highly malignant and exhibits aggressive progression patterns, resists conventional treatments, and poses significant challenges to patient survival, necessitating urgent research and development of novel therapeutic approaches. Understanding …
-
Involvement of The Receptor For Advanced Glycation End Products (Rage) In Progression of Pancreatic Cancer
… is central to several cancer types including pancreatic ductal adenocarcinoma (PDAC), but has been determined to be “undruggable”. Recent studies have indicated that oncogenic <em>KRAS</em> is not constitutively active but relies on a feed-forward stimulatory mechanism involving inflammation. …
-
Investigating The Role of Cd109 In Pancreatic Ductal Adenocarcinoma
<p>Pancreatic Ductal Adenocarcinoma (PDAC) is the 3rd leading cause of cancer death in the US. We performed loss of function genomic screening on a cohort of four patient derived PDAC cell populations and our data shows a cell surface receptor CD109 to be a common vulnerability, the biologic role …
-
Understanding tumor cell plasticity in spatial transcriptomics with graph attention networks and walk-based pseudotime analysis
… maps differentiation pathways. When applied to pancreatic ductal adenocarcinoma (PDAC), distinct, conserved neighborhoods within the tissue, including diverse immune and cancer clusters. By estimating a differentiation path from epithelial to mesenchymal-like cells, we can identify intermediate …
-
Fibroblast Heterogeneity In Pancreatic Cancer Immunity
… were thought to be a barrier to treatment of pancreatic ductal adenocarcinoma (PDAC). However, general stromal targeting strategies have largely failed in the clinic likely due to the heterogeneity of CAFs in the TME. Therefore, our groups and others have worked to unravel the heterogeneity of …
-
Sensitivity and Specificity of Detecting Premalignant Pancreatic Lesions by Hyperpolarized Magnetic Resonance
<p>Early detection of pancreatic ductal adenocarcinoma (PDAC) is challenging due to asymptomatic nature and deep location of the malignancy within the abdomen. The development of PDAC consists of three different pathways but two arise from the duct, Pancreatic Intraepithelial Neoplasia (PanIN) and …
-
Investigating the Role of the Lysine-Specific Demethylase 4C in Pancreatic Ductal Adenocarcinoma
… involved in chromatin regulation is common in pancreatic ductal adenocarcinoma (PDAC). Lysine demethylase 4C (KDM4C) is one of the chromatin modifying proteins frequently overexpressed across multiple solid cancers and is linked to chromatin instability, increased cell proliferation, and …
-
Dissecting the Role of Novel O-GlcNAcylation of NF-κB in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, with a mere 5-year survival of ~10%. This highlights the urgent need for innovative treatment options for PDAC patients. The nuclear factor κB (NF-κB) is a crucial transcription factor that is constitutively activated …
-
Vestigial-Like 1 Is A Shared Targetable Cancer-Placenta Antigen Expressed By Pancreatic and Basal-Like Breast Cancers
… antigens (TAA). To expand the TAA landscape of pancreatic ductal adenocarcinoma (PDAC), we performed tandem mass spectrometry analysis of HLA class I-bound peptides from tumors of PDAC patients. This led to the identification of a shared HLA-A*0101 restricted peptide derived from …
-
MicroRNAs in Pancreatic Ductal Adenocarcinoma: New Approaches For Better Diagnosis And Therapy
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies with less than an 8% 5-year survival rate, which has remained unchanged over the last 50 years. Early detection is particularly difficult due to the lack of disease-specific symptoms and reliable diagnostic …
Page 1 of 6